Evidence map›Paper›PMID 40277233›Full record

ArticleBrain : a journal of neurology2026

A mouse model of GRIN2D developmental and epileptic encephalopathy recapitulates the human disease.

Mor Yam, Jolan Nassir, Danielle Galber, Shir Quinn, Roni Gal, Mor Ovadia, Mor Bordeynik-Cohen, Eden Peled, Christopher D Makinson, Moran Hausman-Kedem and 4 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mor YamDepartment of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6139001, Israel.ORCID 0009-0009-9534-8037
Jolan NassirDepartment of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6139001, Israel.ORCID 0009-0003-7718-6376
Danielle GalberDepartment of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0009-0006-4664-3994
Shir QuinnDepartment of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6139001, Israel.ORCID 0000-0001-9737-5535
Roni GalDepartment of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6139001, Israel.
Mor OvadiaSagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
Mor Bordeynik-CohenDepartment of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-9735-7596
Eden PeledDepartment of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0009-0002-8020-3176
Christopher D MakinsonDepartment of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-1427-8148
Moran Hausman-KedemPediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.ORCID 0000-0001-5315-3738
Aviva Fattal-ValevskiSagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-2867-1685
Wayne N FrankelCenter for Translational Research in Neurodevelopmental Disease, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0003-2241-5314
Karen B AvrahamDepartment of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-4913-251X
Moran RubinsteinDepartment of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6139001, Israel.ORCID 0000-0003-2617-2276

Funding

GENETIC DETERMINANTS OF EPILEPSY IN MURINE SYSTEMSR01NS031348 · NINDS · JACKSON LABORATORY · PI SANDS, TRISTAN T · 1993 to 2025
$11.5M
The Jackson Laboratory Center for Precision Genetics: From New Models to Novel TherapeuticsU54OD020351 · OD · JACKSON LABORATORY · PI FRANKEL, WAYNE N. · 2015 to 2019
$10.2M
Thalamocortical network dysfunction in a novel genetic model of GRIN2D developmental and epileptic encephalopathyR21NS121980 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRANKEL, WAYNE N., MAKINSON, CHRISTOPHER DONALD · 2021 to 2021
$446k
GRIN2D Project FoundationIsrael Science Foundation 214/22NIH HHS R01-NS031348NIH HHS R21-NS121980NIH HHS U54 OD020351NIH HHS U54-OD020351NINDS NIH HHS R01 NS031348NINDS NIH HHS R21 NS121980Tel Aviv University Prajs-Drimmer Institute for Development of Anti-Degenerative DrugsU.S.-Israel Binational Science Foundation #2019065
6 · The paper itself

Abstract

Pathogenic variants in GRIN2D, encoding one of the subunits of the N-methyl-D-aspartate receptor (NMDAR), are associated with developmental and epileptic encephalopathies (DEEs). Unusual for de novo mutations, the recurrent, de novo, gain of function, missense mutation c.1999G>A (p.Val667Ile) was discovered in multiple patients. We characterized a mouse model carrying the orthologous Grin2d mutation, using behavioural paradigms, electrophysiological recordings in acute brain slices focusing mainly on the activity of Purkinje neurons in the cerebellum, and electrocorticography (ECoG) recordings monitoring brain activity and the response to several drugs. Grin2d mutant mice exhibit a range of phenotypes that closely mirror the human disease, including premature mortality, spontaneous seizures and early onset of motor deficits followed by cognitive impairment. In addition, we observed complex developmental changes in Purkinje neurons with reduced spontaneous firing in immature mice and augmented synaptic response to NMDA application in older mice. ECoG recordings demonstrated profound and continuous abnormal brain activity, with altered spectral properties and a prominent narrowband activity in the theta, alpha and beta bands, paralleling the patterns seen in a patient with the same GRIN2D pathogenic variant. Acute administration of ketamine at a low dose (0.5 mg/kg) had a limited effect on the spectral properties, and higher dosages (4 or 10 mg/kg) caused seizures. Conversely, memantine (10 mg/kg) and phenytoin (30 mg/kg) demonstrated a small corrective effect on ECoG properties. Together, Grin2d mutant mice recapitulate key phenotypes of patients with pathogenic GRIN2D variants, including unique, abnormal brain oscillations, which may serve as a biomarker for quantifying drug responses and guiding future research efforts.

Indexed as

Disease Models, AnimalEpilepsyReceptors, N-Methyl-D-AspartateAnimalsBrainElectroencephalographyFemaleHumansMaleMiceMice, Inbred C57BLPurkinje CellsNR2D NMDA receptorReceptors, N-Methyl-D-Aspartatedevelopmental epilepsydrug responseECoGGRIN2Dmouse model

Identifiers

PMID40277233
PMCPMC12782175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.